Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Merger 11
Isotechnika Pharma And Aurinia Pharma Complete Merger 11
Equity Offering 13
Aurinia Pharma Files Shelf Prospectus to Raise up to USD250 Million in Public Offering of Securities 13
Aurinia Pharma Raises USD173.1 Million in Public Offering of Shares 14
Aurinia Pharma Raises USD28.8 Million in Public Offering of Units 16
Aurinia Pharma Raises USD7 Million in Private Placement of Shares 18
Aurinia Pharma Completes Private Placement Of Units For US$52 Million 19
Asset Transactions 21
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 21
Aurinia Pharmaceuticals Inc – Key Competitors 22
Aurinia Pharmaceuticals Inc – Key Employees 23
Aurinia Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 09, 2018: Aurinia reports second quarter financial results and operational highlights 25
May 10, 2018: Aurinia Announces 2018 First Quarter Financial Results 27
Mar 15, 2018: Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 29
Nov 14, 2017: Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights 31
Aug 10, 2017: Aurinia Reports Second Quarter 2017 Financial Results, and Provides Operational Highlights 32
May 15, 2017: Aurinia Reports First Quarter 2017 Financial Results 33
Mar 09, 2017: Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights 35
Corporate Communications 37
Feb 22, 2018: Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors 37
Feb 08, 2018: Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors 38
Dec 11, 2017: Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index 39
Feb 06, 2017: Aurinia Pharmaceuticals appoints chairman and CEO 40
Product News 41
03/27/2017: Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017) 41
03/06/2017: Aurinia Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings 42
02/06/2017: Aurinia Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer 43
Clinical Trials 44
Oct 20, 2017: Aurinia Launches Development Program for Treatment of Dry Eye Syndrome 44
Mar 01, 2017: Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study 45
Feb 14, 2017: Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin 46
Jan 27, 2017: Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial 47
Other Significant Developments 48
Feb 14, 2018: Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurinia Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Isotechnika Pharma And Aurinia Pharma Complete Merger 11
Aurinia Pharma Files Shelf Prospectus to Raise up to USD250 Million in Public Offering of Securities 13
Aurinia Pharma Raises USD173.1 Million in Public Offering of Shares 14
Aurinia Pharma Raises USD28.8 Million in Public Offering of Units 16
Aurinia Pharma Raises USD7 Million in Private Placement of Shares 18
Aurinia Pharma Completes Private Placement Of Units For US$52 Million 19
Ciclofilin Pharma Acquires NICAMs Assets from Aurinia Pharma 21
Aurinia Pharmaceuticals Inc, Key Competitors 22
Aurinia Pharmaceuticals Inc, Key Employees 23
Aurinia Pharmaceuticals Inc, Other Locations 24
Aurinia Pharmaceuticals Inc, Subsidiaries 24
List of Figures
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aurinia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9